← Back to Search

Loop Diuretic

Administration of furosemide for Kidney Failure

Phase 4
Waitlist Available
Led By Marc B Goldstein, MD
Research Sponsored by Unity Health Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Inclusion Criteria:all patients taking Furosemide -
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights

Study Summary

Patients often begin dialysis taking diuretics (stimulate the kidney to excrete salt and water). Once on dialysis, these drugs are often continued. Whether these drugs are still needed, or even effective is often unclear.This study,by evaluating the composition of the patients' urine when off the drug, will predict which patients should benefit from the drug. By comparing their 24 hour volume both off and on the drug, the impact of the drug will be established. The results will allow the prediction of which patients, in the future, should take the drug. The hypothesis is: Among dialysis recipients, evaluation of the random urine sodium concentration will help predict the likelihood of a positive response to Furosemide, as manifested by an increased urine volume and sodium excretion.

Eligible Conditions
  • Kidney Failure

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
24 hour urine sodium and water excretion
Secondary outcome measures
Interdialytic weight gain
Other outcome measures
The patients' BP on and off the drug will be compared

Side effects data

From 2017 Phase 4 trial • 57 Patients • NCT01441245
27%
rehospitalization for all cardiovascular causes
20%
death
100%
80%
60%
40%
20%
0%
Study treatment Arm
cIV Group
iIV Group

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Administration of furosemideExperimental Treatment1 Intervention
The patient will receive furosemide 120 mgms daily
Group II: Withdrawal of FurosemideActive Control1 Intervention
The patient's Furosemide will be withdrawn

Find a Location

Who is running the clinical trial?

Unity Health TorontoLead Sponsor
541 Previous Clinical Trials
447,789 Total Patients Enrolled
1 Trials studying Kidney Failure
215 Patients Enrolled for Kidney Failure
Marc B Goldstein, MDPrincipal InvestigatorUnity Health Toronto

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby May 2025